Tilray Brands, Inc. (2HQ.DE)
EUR 1.16
(0.43%)
EUR 1.16
(0.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -72.84 Million USD | 126.62% |
| 2022 | -1.27 Billion USD | -142.8% |
| 2021 | -246.4 Million USD | 786.85% |
| 2020 | 30.27 Million USD | -54.92% |
| 2019 | -47.87 Million CAD | 367.85% |
| 2018 | -15.04 Million CAD | 2062.99% |
| 2017 | 34.03 Million CAD | -116.73% |
| 2016 | 4.37 Million CAD | 4014.4% |
| 2015 | 115.11 Thousand CAD | 97.8% |
| 2014 | -5.06 Million CAD | -283.22% |
| 2013 | -1.32 Million USD | -2814.33% |
| 2012 | -45.33 Thousand CAD | 53.98% |
| 2011 | -98.51 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.89 Million USD | 82.14% |
| 2023 Q1 | -7.63 Million USD | -9.91% |
| 2023 Q4 | 25.42 Million USD | 268.55% |
| 2023 Q3 | -15.08 Million USD | -267.39% |
| 2023 FY | - USD | 126.62% |
| 2023 Q2 | -4.1 Million USD | 46.19% |
| 2022 Q4 | -6.94 Million USD | 86.95% |
| 2022 FY | - USD | -142.8% |
| 2022 Q3 | -53.21 Million USD | -38.69% |
| 2022 Q2 | -38.36 Million USD | -5334.24% |
| 2022 Q1 | 733 Thousand USD | -99.76% |
| 2021 FY | - USD | 786.85% |
| 2021 Q4 | 299.37 Million USD | 498.25% |
| 2021 Q1 | -27.54 Million USD | -408.64% |
| 2021 Q3 | 50.04 Million USD | 630.78% |
| 2021 Q2 | -9.42 Million USD | 65.77% |
| 2020 Q3 | -23.93 Million CAD | 65.43% |
| 2020 Q2 | -69.23 Million USD | -318.6% |
| 2020 FY | - USD | -54.92% |
| 2020 Q4 | 8.92 Million USD | 137.29% |
| 2020 Q1 | 31.67 Million USD | -35.35% |
| 2019 Q2 | 41.28 Million USD | 72.17% |
| 2019 Q3 | 38.96 Million USD | -5.61% |
| 2019 Q4 | 48.98 Million USD | 25.71% |
| 2019 FY | - CAD | 367.85% |
| 2019 Q1 | 23.97 Million USD | -42.83% |
| 2018 Q1 | -2.72 Million USD | -186.01% |
| 2018 FY | - CAD | 2062.99% |
| 2018 Q4 | 41.94 Million USD | 369.97% |
| 2018 Q3 | -15.53 Million USD | -157.12% |
| 2018 Q2 | 27.2 Million USD | 1099.34% |
| 2017 Q4 | 3.16 Million USD | 1161.9% |
| 2017 FY | - CAD | -116.73% |
| 2017 Q3 | -298.02 Thousand USD | -134.15% |
| 2017 Q1 | -4.53 Million USD | -296.77% |
| 2017 Q2 | 872.63 Thousand USD | 119.26% |
| 2016 FY | - CAD | 4014.4% |
| 2016 Q4 | 2.3 Million USD | 150.0% |
| 2016 Q1 | 1.05 Million CAD | 260.92% |
| 2016 Q3 | -4.6 Million USD | -597.14% |
| 2016 Q2 | 926.49 Thousand CAD | -12.58% |
| 2015 Q1 | -291.38 Thousand CAD | 20.26% |
| 2015 Q3 | 115.01 Thousand CAD | 147.38% |
| 2015 Q4 | 293.63 Thousand CAD | 155.3% |
| 2015 FY | - CAD | 97.8% |
| 2015 Q2 | -242.73 Thousand CAD | 16.7% |
| 2014 Q4 | -365.43 Thousand CAD | 84.96% |
| 2014 Q3 | -2.42 Million CAD | -37386.56% |
| 2014 Q2 | -6482.23 CAD | 22.05% |
| 2014 Q1 | -8316.12 CAD | 86.85% |
| 2014 FY | - CAD | -283.22% |
| 2013 Q3 | -47.23 Thousand CAD | -933.36% |
| 2013 Q4 | -63.26 Thousand CAD | -33.93% |
| 2013 Q1 | -7855.65 CAD | -73.67% |
| 2013 FY | - USD | -2814.33% |
| 2013 Q2 | -4571.06 CAD | 41.81% |
| 2012 Q1 | -13.65 Thousand CAD | 24.11% |
| 2012 Q2 | -20.45 Thousand CAD | -49.81% |
| 2012 Q3 | -13.33 Thousand CAD | 34.84% |
| 2012 FY | - CAD | 53.98% |
| 2012 Q4 | -4523.23 CAD | 66.07% |
| 2011 Q4 | -17.99 Thousand CAD | 72.63% |
| 2011 Q3 | -65.73 Thousand CAD | -1819.75% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | -3424.37 CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| MPH Health Care AG | 33.31 Million EUR | 318.656% |
| Apontis Pharma AG | -12.94 Million EUR | -462.871% |
| Dermapharm Holding SE | 277.29 Million EUR | 126.269% |
| Evotec SE | 7.82 Million EUR | 1031.139% |
| MERCK Kommanditgesellschaft auf Aktien | 5.52 Billion EUR | 101.319% |
| PharmaSGP Holding SE | 35.86 Million EUR | 303.086% |
| SynBiotic SE | -7.12 Million EUR | -922.703% |